Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 2/20 | 0.32 |
| ▸ | POLB | P06746 | 2/20 | 0.32 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.32 |
| ▸ | GAA | P10253 | 1/20 | 0.31 |
| ▸ | RECQL | P46063 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
| ▸ | IDUA | P35475 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | CACNA1B | Q00975 | 1/20 | 0.31 |
| ▸ | APBA1 | Q02410 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14584179 | 1.00 | CYP3A4 (0.33) | CYP3A4TSHRPOLBMAPK1GAA | |
| SCHEMBL4096506 | 1.00 | CYP3A4 (0.33) | CYP3A4TSHRPOLBMAPK1GAA | |
| SCHEMBL2152162 | 1.00 | CYP3A4 (0.33) | CYP3A4TSHRPOLBMAPK1GAA | |
| SCHEMBL19155610 | 0.83 | FUCA1 (0.33) | CYP3A4TSHRPOLBMAPK1GAA | |
| SCHEMBL712837 | 0.79 | CYP3A4 (0.39) | CYP3A4TSHRPOLBMAPK1GAA | |
| SCHEMBL28475631 | 0.78 | LGALS3 (0.33) | IDUA | |
| SCHEMBL2189191 | 0.77 | TSHR (0.45) | TSHR | |
| SCHEMBL2189182 | 0.77 | TSHR (0.45) | TSHR | |
| SCHEMBL28214269 | 0.77 | AHCY (0.34) | IDUA | |
| SCHEMBL14614369 | 0.76 | POLB (0.32) | CYP3A4TSHRPOLBMAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-111278817-B | Polycyclic compounds as farnesol X receptor modulators | 百时美施贵宝公司 | 2023-05-16 | — | — | CN | disclosed |